Effect of systemic melatonin in periodontal therapy

Evaluation of the effect of systemically administered melatonin in patients undergoing regenerative surgical periodontal therapy- a double blind placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048262

Enrollment

Registered

2022-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M278- Other specified diseases of jaws

Interventions

Intervention1: Melatonin: Melatonin 3 mg, systemically administered once a day after food in the night for 30 days Control Intervention1: Placebo: Sugar tablet as placebo, taken once a day after food

similar to intervention group.

Eligibility

Inclusion criteria

Inclusion criteria: 1.systemically healthy Subjects with periodontal disease indicated for flap surgery 2. Subjects with three/two walled intrabony defects that can be regenerated

Exclusion criteria

Exclusion criteria: 1. Subjects without periodontal disease 2. Subjects with periodontal disease not requiring regenerative therapy

Design outcomes

Secondary

Measure	Time frame
Clinical parameters: probing depth, clinical attachment lossTimepoint: Base line, 3 months;Levels of melatoninTimepoint: Baseline, 1 month	—

Primary

Measure	Time frame
Level of alkaline phosphatase and bone sialoprotein at baseline and 4 weeks after interventionTimepoint: at baseline and 4 weeks after intervention	—

Countries

India

Contacts

Public ContactDr Sankari Malaiappan

Saveetha Dental College and Hospitals

Sankari@saveetha.com9840285905

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026